Abstract: Inhibitors of Glycerol 3-Phosphate Acyltransferase (GPAT) are provided; and methods of use in the treatment of cancer; and treatment of conditions relating to metabolic syndrome and hyperlipidemia.

Abstract: Methods of inhibiting the proliferation of a cancer cell, and treating cancer in an individual are provided. Aspects of the subject methods include contacting a cancer cell with an azapodophyllotoxin derivative, where the contacting is effective to inhibit tubulin polymerization and monoglycerol metabolism to inhibit proliferation of cancer in the cell. In certain cases, the cancer cell is a renal cancer cell (RCC) or a lymphoma cell. Aspects of the methods also include administering to a subject an effective amount of an azapodophyllotoxin derivative to treat the subject for cancer, where the cancer is selected from renal cancer and lymphoma. Also provided is a method of monitoring tumor regression in an individual, and methods of identifying a cancer suppressing compound.

Abstract: Inhibitors of Glycerol 3-Phosphate Acyltransferase (GPAT) are provided; and methods of use in the treatment of cancer; and treatment of conditions relating to metabolic syndrome, hyperlipidemia, infection and inflammation.

Abstract: Provided are methods of identifying MYC-Driven and/or lipogenesis-dependent neoplasms. Also provided are methods of treating the MYC-Driven neoplasms and methods of treating lipogenesis-dependent neoplasms. Methods of identifying therapeutic agents that are effective against MYC-driven neoplasms are also provided.

Abstract: Inhibitors of Glycerol 3-Phosphate Acyltransferase (GPAT) are provided; and methods of use in the treatment of cancer; and treatment of conditions relating to metabolic syndrome and hyperlipidemia.

Abstract: Methods are provided for the detection and treatment of cancers having a KRAS mutation, which KRAS mutation may drive tumorigenesis in the cancer. In some embodiments the KRAS+ cancer is a lung adenocarcinoma.

Abstract: A nanoimmunoassay (NIA) is applied to quantify analytes, including without limitation proteins and isoforms of proteins involved in oncogenic or metabolic signaling pathways, in a small amount of lysate from a tissue sample. Samples of interest for NIA include without limitation blood or solid tumor microbiopsy samples, such as fine needle aspirate (FNA) or circulating tumor cells. Samples may be taken at a single timepoint, or may be taken at multiple timepoints. Samples may be as small as 100,000 cells, as small as 5000 cells, as small as 1000 cells, as small as 100 cells, as small as 50 cells, as small as 25 cells or less. The NIA detection method combines size separation of proteins or isoelectric protein focusing and antibody detection in a microfluidic system.